Thrombophilia means a predisposition to thrombosis. It is defined as an abnormality of the coagulation or fibrinolytic system that results in a hypercoagulable state and therefore increases the risk of thrombosis. This pathology has a high risk of pregnancy termination, preeclampsia, placental insufficiency and placental abruption, and recurrent pregnancy loss (RPN). Thrombophilia also increases the risk of venous thromboembolism.
There are two types of thrombophilia: genetic (thrombin, Protein S or Protein C deficiency), also called hereditary or congenital, and acquired (antiphospholipid syndrome, nephrotic syndrome).
Thrombophilia is diagnosed on the basis of medical history, physical examination and instrumental and laboratory tests.
Genomics, the high-tech biomedical research and genetic diagnostics center provides tests of high accuracy, quality and reliability using the PCR amplification method.
Factor V Leiden (G1691A);
V Factor (H1299R);
Factor II Prothrombin (G20210A);
MTHFR (C677T);
MTHFR (A1298C);
PAI-1 (4G/5G);
XIII Factor (V34L).
In case of confirmed thrombophilia, the basis of thrombosis prevention is a healthy lifestyle, including physical activity, smoking cessation, proper diet and body weight correction.
If thrombophilia is diagnosed and there are additional risk factors for thrombosis, consideration shall be given to medical preventive treatment, administered as anticoagulants or antiplatelet agents as indicated.
It is possible that a person has thrombophilia and for years it does not manifest clinically. Thrombophilia is manifested by thrombosis, the symptoms of which depend on the location of the clot.
The causes of thrombophilia include: